An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells
IMM van Leeuwen, B Rao, MCC Sachweh, S Laín - Cell cycle, 2012 - Taylor & Francis
Pharmacological activation of wild-type p53 has been found to protect normal cells in culture
from cytotoxicity and nuclear aberrations caused by conventional cancer therapeutics …
from cytotoxicity and nuclear aberrations caused by conventional cancer therapeutics …
Nongenotoxic p53 activation protects cells against S-phase–specific chemotherapy
D Kranz, M Dobbelstein - Cancer research, 2006 - AACR
Mutations in the tumor suppressor gene TP5 3 represent the most frequent genetic
difference between tumor cells and normal cells. Here, we have attempted to turn this …
difference between tumor cells and normal cells. Here, we have attempted to turn this …
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy
The activation of p53 has been proposed as a novel anti-cancer treatment in two distinct
contexts. In the first activation of p53 in tumor cells can promote apoptosis and senescence …
contexts. In the first activation of p53 in tumor cells can promote apoptosis and senescence …
Wild-type p53 protects normal cells against apoptosis induced by thiostrepton
M Halasi, DP Schraufnagel, AL Gartel - Cell Cycle, 2009 - Taylor & Francis
Cancer cells are generally more sensitive to anticancer drugs than normal cells. This
provides the rationale for using anticancer drugs specifically against tumor cells, but the …
provides the rationale for using anticancer drugs specifically against tumor cells, but the …
p53-Based cyclotherapy: exploiting the 'guardian of the genome'to protect normal cells from cytotoxic therapy
B Rao, S Lain, AM Thompson - British journal of cancer, 2013 - nature.com
Side effects of chemotherapy are a major impediment in the treatment of cancer.
Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side …
Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side …
Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors
EA Komarova, AV Gudkov - Biochemical pharmacology, 2001 - Elsevier
The p53 tumor suppressor pathway is a key mediator of stress response that protects the
organism from accumulating genetically altered and potentially cancerous cells by inducing …
organism from accumulating genetically altered and potentially cancerous cells by inducing …
Pharmacological activation of p53 in cancer cells
M Athar, CA Elmets… - Current pharmaceutical …, 2011 - ingentaconnect.com
Tumor suppressor p53 is a transcription factor that regulates a large number of genes and
guards against genomic instability. Under multiple cellular stress conditions, p53 functions to …
guards against genomic instability. Under multiple cellular stress conditions, p53 functions to …
p53-based cancer therapy
Inactivation of p53 functions is an almost universal feature of human cancer cells. This has
spurred a tremendous effort to develop p53 based cancer therapies. Gene therapy using …
spurred a tremendous effort to develop p53 based cancer therapies. Gene therapy using …
Wild-type p53 in cancer cells: when a guardian turns into a blackguard
E Kim, A Giese, W Deppert - Biochemical pharmacology, 2009 - Elsevier
The tumor suppressor p53 controls a broad range of cellular responses. Induction of a
transient (cell cycle arrest) or a permanent (senescence) block of cell proliferation, or the …
transient (cell cycle arrest) or a permanent (senescence) block of cell proliferation, or the …